275 related articles for article (PubMed ID: 28164427)
1. Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.
van Dessel LF; Beije N; Helmijr JC; Vitale SR; Kraan J; Look MP; de Wit R; Sleijfer S; Jansen MP; Martens JW; Lolkema MP
Mol Oncol; 2017 Mar; 11(3):295-304. PubMed ID: 28164427
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of circulating tumor DNA stability In K
Kang Q; Henry NL; Paoletti C; Jiang H; Vats P; Chinnaiyan AM; Hayes DF; Merajver SD; Rae JM; Tewari M
Clin Biochem; 2016 Dec; 49(18):1354-1360. PubMed ID: 27129799
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
[No Abstract] [Full Text] [Related]
4. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
[TBL] [Abstract][Full Text] [Related]
5. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR.
Norton SE; Lechner JM; Williams T; Fernando MR
Clin Biochem; 2013 Oct; 46(15):1561-5. PubMed ID: 23769817
[TBL] [Abstract][Full Text] [Related]
6. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
Medina Diaz I; Nocon A; Mehnert DH; Fredebohm J; Diehl F; Holtrup F
PLoS One; 2016; 11(11):e0166354. PubMed ID: 27832189
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Merker JD; Oxnard GR; Compton C; Diehn M; Hurley P; Lazar AJ; Lindeman N; Lockwood CM; Rai AJ; Schilsky RL; Tsimberidou AM; Vasalos P; Billman BL; Oliver TK; Bruinooge SS; Hayes DF; Turner NC
J Clin Oncol; 2018 Jun; 36(16):1631-1641. PubMed ID: 29504847
[TBL] [Abstract][Full Text] [Related]
8. Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics.
van Ginkel JH; van den Broek DA; van Kuik J; Linders D; de Weger R; Willems SM; Huibers MMH
Cancer Med; 2017 Oct; 6(10):2297-2307. PubMed ID: 28940814
[TBL] [Abstract][Full Text] [Related]
9. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
Sherwood JL; Corcoran C; Brown H; Sharpe AD; Musilova M; Kohlmann A
PLoS One; 2016; 11(2):e0150197. PubMed ID: 26918901
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples.
Nesic M; Bødker JS; Terp SK; Dybkær K
Biomed Res Int; 2021; 2021():5585148. PubMed ID: 34307658
[TBL] [Abstract][Full Text] [Related]
11. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms.
van Dessel LF; Vitale SR; Helmijr JCA; Wilting SM; van der Vlugt-Daane M; Oomen-de Hoop E; Sleijfer S; Martens JWM; Jansen MPHM; Lolkema MP
Mol Oncol; 2019 Feb; 13(2):392-402. PubMed ID: 30516338
[TBL] [Abstract][Full Text] [Related]
12. Circulating cell-free DNA in cancer.
Pinzani P; Salvianti F; Orlando C; Pazzagli M
Methods Mol Biol; 2014; 1160():133-45. PubMed ID: 24740228
[TBL] [Abstract][Full Text] [Related]
13. Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients.
Marsavela G; Reid A; Gray ES; Calapre L
Methods Mol Biol; 2021; 2265():247-263. PubMed ID: 33704720
[TBL] [Abstract][Full Text] [Related]
14. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample.
Rothwell DG; Smith N; Morris D; Leong HS; Li Y; Hollebecque A; Ayub M; Carter L; Antonello J; Franklin L; Miller C; Blackhall F; Dive C; Brady G
Mol Oncol; 2016 Apr; 10(4):566-74. PubMed ID: 26639657
[TBL] [Abstract][Full Text] [Related]
15. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
16. Performance of ImproGene cfDNA blood collection tubes for mutation analysis in cancer patients.
Zhang S; Zhou D; Li S; Bai Y; Huang B; Han J; Xu M; Wang S; Deng G
Scand J Clin Lab Invest; 2022 Sep; 82(5):378-384. PubMed ID: 35861435
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
18. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
[TBL] [Abstract][Full Text] [Related]
19. Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer.
Vitale SR; Helmijr JA; Gerritsen M; Coban H; van Dessel LF; Beije N; van der Vlugt-Daane M; Vigneri P; Sieuwerts AM; Dits N; van Royen ME; Jenster G; Sleijfer S; Lolkema M; Martens JWM; Jansen MPHM
BMC Cancer; 2021 Mar; 21(1):315. PubMed ID: 33761899
[TBL] [Abstract][Full Text] [Related]
20. Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.
Ahlborn LB; Madsen M; Jonson L; Nielsen FC; Lassen U; Yde CW; Mau-Sorensen M
Clin Lab; 2017 Oct; 63(10):1755-1759. PubMed ID: 29035458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
